FY2025 · ended Dec 31, 2025 · Revenue $100.25M, +53.9% YoY · Filed Feb 24, 2026
Beta Bionics, Inc. (BBNX) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $100.3 million and a net loss of $73.2 million. Free cash flow was -$56.2 million. As of Sep 30, 2026 it held $373.6 million in cash and investments and $6.1 million in total debt.
Revenue (TTM)
$127.27M
Net income (TTM)
$-83.12M
Operating cash flow (TTM)
$-59.37M
Free cash flow (TTM)
$-65.96M
EPS (TTM)
$-1.85
Dividend per share
None
Shares outstanding
44.38M
+2.4% vs prior year
Net cash
$367.54M
as of Sep 30, 2026
Operating margin
-72.7%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- BBNX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1674632
- Former names
- Beta Bionics, Inc (until Jan 6, 2025)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $100.3M | $65.1M |
| Operating income | -$71.7M | -$45.3M |
| Net income | -$73.2M | -$54.8M |
| Diluted EPS | -$1.81 | -$8.60 |
| Operating cash flow | -$50.9M | -$48.3M |
| Free cash flow | -$56.2M | -$51.7M |
| Total assets | $328.7M | $149.6M |
| Total liabilities | $41.1M | $73.6M |
| Stockholders' equity | $287.6M | -$245.4M |
| Cash and investments | $264.6M | $103.6M |
| Total debt | $7.3M | $7.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 27, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Other events
|
Sep 17, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 15, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
All 285 Beta Bionics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.